» Articles » PMID: 37606757

Hsa_circ_0031891 Targets MiR-579-3p to Enhance HMGB1 Expression and Regulate PDGF-BB-induced Human Aortic Vascular Smooth Muscle Cell Proliferation, Migration, and Dedifferentiation

Overview
Specialty Pharmacology
Date 2023 Aug 22
PMID 37606757
Authors
Affiliations
Soon will be listed here.
Abstract

Atherosclerosis (AS) is an underlying cause of the majority of coronary artery disease (CAD), in which proliferation, migration, and dedifferentiation of vascular smooth muscle cells (VSMCs) exert vital roles. It has been reported that circular RNAs (circRNAs) are associated with the VSMCs function. Here, we undertook to explore the biological function and mechanism of hsa_circ_0031891 in a platelet-derived growth factor-BB (PDGF-BB)-induced AS cell model. Hsa_circ_0031891 and microRNA-579-3p (miR-579-3p) levels were detected by real-time quantitative polymerase chain reaction (RT-qPCR). Cell proliferation and migration were detected using Cell Counting Kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EdU), wound healing, and transwell assay. Protein levels of alpha-smooth muscle actin (α-SMA), smooth muscle protein 22-α (SM22-α), Osteopontin, and High mobility group box-1 (HMGB1) were determined using western blot assay. After predicting via a variety of bioinformatics software, the binding between miR-579-3p and hsa_circ_0031891 or HMGB1 was validated using dual-luciferase reporter and RNA pull-down assays. Increased hsa_circ_0031891 and HMGB1 and reduced miR-579-3p were found in CAD patients and PDGF-BB-induced human aortic vascular smooth muscle cells (HA-VSMCs). Moreover, hsa_circ_0031891 deficiency relieved PDGF-BB-mediated HA-VSMC proliferation, migration, and dedifferentiation. Mechanically, hsa_circ_0031891 modulated HMGB1 expression via sponging miR-579-3p. Hsa_circ_0031891 boosted PDGF-BB-induced proliferation, migration, and dedifferentiation partly by regulating the miR-579-3p/HMGB1 axis, hinting at a feasible therapeutic strategy for AS.

Citing Articles

Targeting PDGF/PDGFR Signaling Pathway by microRNA, lncRNA, and circRNA for Therapy of Vascular Diseases: A Narrow Review.

Ma C, Shi S, Zhang X, Xin G, Zou X, Li W Biomolecules. 2024; 14(11).

PMID: 39595622 PMC: 11592287. DOI: 10.3390/biom14111446.


Circular RNAs in coronary heart disease: From molecular mechanism to promising clinical application (Review).

Fan Z, Yuan X, Yuan Y Int J Mol Med. 2024; 55(1).

PMID: 39513584 PMC: 11573316. DOI: 10.3892/ijmm.2024.5452.

References
1.
Altesha M, Ni T, Khan A, Liu K, Zheng X . Circular RNA in cardiovascular disease. J Cell Physiol. 2018; 234(5):5588-5600. DOI: 10.1002/jcp.27384. View

2.
Beermann J, Piccoli M, Viereck J, Thum T . Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol Rev. 2016; 96(4):1297-325. DOI: 10.1152/physrev.00041.2015. View

3.
Bennett M, Sinha S, Owens G . Vascular Smooth Muscle Cells in Atherosclerosis. Circ Res. 2016; 118(4):692-702. PMC: 4762053. DOI: 10.1161/CIRCRESAHA.115.306361. View

4.
Chen Y, Li C, Tan C, Liu X . Circular RNAs: a new frontier in the study of human diseases. J Med Genet. 2016; 53(6):359-65. DOI: 10.1136/jmedgenet-2016-103758. View

5.
Chen Z, Pan X, Sheng Z, Yan G, Chen L, Ma G . Baicalin Suppresses the Proliferation and Migration of Ox-LDL-VSMCs in Atherosclerosis through Upregulating miR-126-5p. Biol Pharm Bull. 2019; 42(9):1517-1523. DOI: 10.1248/bpb.b19-00196. View